Zura Bio Limited Class A Ordinary Shares Cash Flow Conversion Efficiency
Zura Bio Limited Class A Ordinary Shares cash flow conversion efficiency. Based on the latest financial reports, Zura Bio Limited Class A Ordinary Shares (ZURA) has a cash flow conversion efficiency ratio of -0.130x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.44 Million) by net assets ($118.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Zura Bio Limited Class A Ordinary Shares (2021–2024)
Cash flow conversion efficiency of Zura Bio Limited Class A Ordinary Shares from 2021 to 2024. This chart illustrates how Zura Bio Limited Class A Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Zura Bio Limited Class A Ordinary Shares for real-time trading data and today's change.
Zura Bio Limited Class A Ordinary Shares Cash Flow Conversion Ratio Explained
Zura Bio Limited Class A Ordinary Shares cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Zura Bio Limited Class A Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zura Bio Limited Class A Ordinary Shares ranked by their cash flow conversion efficiency. Also see Zura Bio Limited Class A Ordinary Shares (ZURA) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Newron Pharmaceuticals SpA
SW:NWRN
|
0.119x |
|
Aviat Networks Inc
NASDAQ:AVNW
|
0.012x |
|
G1 Secure Solutions Ltd
TA:GOSS
|
-0.007x |
|
Fagerhult AB
ST:FAG
|
0.049x |
|
Secuoya Grupo de Comunicación S.A
MC:SEC
|
0.018x |
|
Monogram Orthopaedics Inc. Common Stock
NASDAQ:MGRM
|
-0.267x |
|
Highview Merger Corp. Class A Ordinary Share
NASDAQ:HVMC
|
0.016x |
|
Sichuan Langsha Holding Ltd
SHG:600137
|
-0.016x |
Annual Cash Flow Conversion Efficiency for Zura Bio Limited Class A Ordinary Shares (2021–2024)
The table below shows the annual cash flow conversion efficiency of Zura Bio Limited Class A Ordinary Shares from 2021 to 2024. Review financial flexibility index of Zura Bio Limited Class A Ordinary Shares to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $160.02 Million | $-28.08 Million | -0.175x | +7.28% |
| 2023-12-31 | $79.55 Million | $-15.05 Million | -0.189x | -447.24% |
| 2022-12-31 | $-22.06 Million | $-1.20 Million | 0.054x | +746.14% |
| 2021-12-31 | $130.20 Million | $-1.10 Million | -0.008x | -- |
About Zura Bio Limited Class A Ordinary Shares
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 … Read more